SOCRA Adverse Event Safety Reporting 3

Question 1

In a blinded clinical trial, when is it permissible to break the blind for a subject who experiences an SAE?

Accepted Answer

Only when necessary for appropriate medical management of the subject

Answer

Only after the trial is complete

Answer

Whenever the investigator requests it

Answer

Only with prior IRB/IEC approval in each instance

Question 2

What is the primary purpose of the CIOMS I form in clinical research safety reporting?

Accepted Answer

Reporting individual case safety reports (ICSRs) to regulatory authorities internationally

Answer

Documenting protocol deviations for IRB review

Answer

Enrolling new subjects after a safety hold is lifted

Answer

Recording annual aggregate safety data for the DSUR

Question 3

When a sponsor unblocks treatment assignment to assess causality for an SAE, who should ideally remain blinded to preserve trial integrity?

Accepted Answer

Investigators and study site staff not involved in medical management

Answer

The sponsor's pharmacovigilance safety team

Answer

The regulatory authority receiving the report

Answer

The institutional review board reviewing the protocol

Question 4

The Development Safety Update Report (DSUR) is designed to:

Accepted Answer

Provide a comprehensive annual review of an investigational product's safety profile during clinical development

Answer

Report individual SAEs within 15 days of occurrence

Answer

Submit protocol amendments to regulatory authorities

Answer

Replace the Investigator's Brochure after each trial phase

Question 5

An investigator receives a sponsor safety letter reporting a new SAE from a different site using the same investigational drug. What is the investigator's primary obligation?

Accepted Answer

Notify the IRB/IEC and assess implications for subjects currently enrolled at their site

Answer

Immediately withdraw all enrolled subjects from the trial

Answer

File an independent report directly to the FDA

Answer

Discard the letter as it pertains to another site

Question 6

Which of the following best describes a 'suspected adverse reaction' in the context of IND safety reporting?

Accepted Answer

An AE for which there is a reasonable possibility of a causal relationship to the investigational drug

Answer

Any AE occurring after the first dose regardless of relationship

Answer

An AE that is listed in the Investigator's Brochure as expected

Answer

An AE that resolves without medical intervention

Question 7

How should an investigator handle follow-up information after an initial SAE report is submitted to the sponsor?

Accepted Answer

Follow-up reports must be submitted as new information becomes available until the event resolves or stabilizes

Answer

No follow-up is needed once the initial SAE form is submitted

Answer

Follow-up reports are only required if the subject is hospitalized

Answer

Follow-up is the sponsor's sole responsibility after the initial report